Study of MTP 131 in patients with Fuchs' Corneal Endothelial Dystrophy
Phase of Trial: Phase II
Latest Information Update: 08 Mar 2016
At a glance
- Drugs Elamipretide (Primary)
- Indications Corneal disorders
- Focus Therapeutic Use
- Acronyms ReVEAL
- Sponsors Stealth BioTherapeutics
- 08 Mar 2016 According to Stealth BioTherapeutics media release, top-line data from the study are expected in the third quarter of 2016.
- 08 Mar 2016 Status changed from planning to recruiting, as per Stealth BioTherapeutics media release.
- 27 Jun 2015 New trial record